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ABSTRACT
NMDA receptors (NMDA-Rs) are ionotropic glutamate receptors,
which associate with LDL-receptor-related protein-1 (LRP1) to trigger
cell signaling in response to protein ligands in neurons. Here, we
demonstrate for the first time that the NMDA-R is expressed by rat
Schwann cells and functions independently and with LRP1 to
regulate Schwann cell physiology. The NR1 (encoded by GRIN1)
and NR2b (encoded by GRIN2B) NMDA-R subunits were expressed
by cultured Schwann cells and upregulated in sciatic nerves following
crush injury. The ability of LRP1 ligands to activate ERK1/2 (also
known as MAPK3 and MAPK1, respectively) and promote Schwann
cell migration required the NMDA-R. NR1 gene silencing
compromised Schwann cell survival. Injection of the LRP1 ligands
tissue-type plasminogen activator (tPA, also known as PLAT) or
MMP9-PEX into crush-injured sciatic nerves activated ERK1/2 in
Schwann cells in vivo, and the response was blocked by systemic
treatment with the NMDA-R inhibitor MK801. tPA was unique among
the LRP1 ligands examined because tPA activated cell signaling and
promoted Schwann cell migration by interacting with the NMDA-R
independently of LRP1, albeit with delayed kinetics. These results
define the NMDA-R as a Schwann cell signaling receptor for protein
ligands and a major regulator of Schwann cell physiology, which may
be particularly important in peripheral nervous system (PNS) injury.
KEYWORDS: Schwann cell, Peripheral nerve, NMDA receptor, LRP1,
Tissue-type plasminogen activator, MMP9, α2-macroglobulin
INTRODUCTION
The N-methyl-D-aspartate receptor (NMDA-R) is an extensively
studied neuronal ionotropic glutamate receptor, composed of
GluN1 (NR1, encoded by GRIN1) and GluN2 (NR2, encoded by
GRIN2A–GRIN2D) subunits (Furukawa et al., 2005). Numerous
activities have been described for the NMDA-R in neuronal
development, including effects on cell migration, differentiation of
progenitors and dendrite development (Nacher and McEwen, 2006;
Rajan and Cline, 1998). In mature neurons, the NMDA-R localizes
to post-synaptic densities, where it plays an important role in long-
term potentiation based on its mechanism of channel activation that
requires both glutamate and membrane depolarization (Bliss and
Collingridge, 1993; Lynch, 2004). Ca2+ flux through the NMDA-R
regulates cell signaling and, in turn, activated signaling factors
regulate the function of the NMDA-R (Wang and Salter, 1994).
Abnormal expression and mutations in the NMDA-R have been
implicated in neurological and psychiatric disorders (Kemp and
McKernan, 2002; Jansen and Dannhardt, 2003;Missale et al., 2006;
Brown and Krupp, 2006). Drugs targeting the NMDA-R are used in
anesthesia and pain management (Ji et al., 2003).
In post-synaptic densities in neurons, the NMDA-R is physically
and functionally associated with receptors in the low-density
lipoprotein (LDL) receptor family, including LDL-receptor-related
protein-1 (LRP1) and ApoER2 (also known as LRP8) (Strickland
et al., 2002; May et al., 2004; Hoe et al., 2006; Martin et al., 2008).
Based on its interaction with LRP1, the NMDA-R functions as an
essential signaling co-receptor for LRP1 ligands, including α2-
macroglobulin (α2M), tissue-type plasminogen activator (tPA) and
apolipoprotein E (Bacskai et al., 2000; Qiu et al., 2002; Samson
et al., 2008; Martin et al., 2008; Sheng et al., 2008; Mantuano et al.,
2013). LRP1 ligands have been implicated in neuronal survival
(Hayashi et al., 2007; Fuentealba et al., 2009) and in neurite
outgrowth (Mantuano et al., 2008a,b; Shi et al., 2009; Yoon et al.,
2013). Unlike other LRP1 ligands, tPA interacts directly with the
NMDA-R, independently of LRP1, triggering cell signaling, albeit
with delayed kinetics (Nicole et al., 2001; Macrez et al., 2010;
Ng et al., 2009; Mantuano et al., 2013). NR1 subunit cleavage is
reported to be involved in the mechanism by which tPA activates the
NMDA-R; however, NR1 cleavage might not be necessary (Nicole
et al., 2001; Mantuano et al., 2008a,b).
Less is known about NMDA-Rs in cells other than neurons. The
NMDA-R has been identified in oligodendrocyte processes and
central nervous system (CNS) myelin (Salter and Fern, 2005; Micu
et al., 2006). Cortical astrocytes and satellite cells express NMDA-
Rs, which might be involved in crosstalk with neurons (Lalo et al.,
2006; Castillo et al., 2013). NMDA-Rs also have been identified in
Schwann cells in guinea pig and squid (Evans et al., 1991; Fink
et al., 1999); however, the function of Schwann cell NMDA-R
remains undefined.
Schwann cells provide myelination and trophic support for axons
(Jessen and Mirsky, 2005; Campana, 2007). In response to PNS
injury, Schwann cells de-differentiate and acquire the ability to
migrate and proliferate in a process termed ‘Schwann cell activation’
(Meier et al., 1999; Jopling et al., 2011; Arthur-Farraj et al., 2012).
Activated Schwann cells carry out functions that are essential for
nerve repair, including phagocytosis of debris, secretion of trophic
factors and deposition of provisional extracellular matrix proteins.
LRP1 is expressed by Schwann cells mainly after peripheral nervous
system (PNS) injury (Campana et al., 2006) and functions as a robust
cell signaling receptor (Mantuano et al., 2008a,b, 2010, 2011). LRP1-
initiated cell signaling supports Schwann cell survival and migration.
When LRP1 is deleted conditionally in Schwann cells in mice,
abnormalities in the response to PNS injury are observed, including
accelerated demyelination, abnormal regeneration and neuropathic
pain (Orita et al., 2013). The molecular nature of the LRP1 signaling
system in Schwann cells remains uncharacterized.Received 29 April 2015; Accepted 6 August 2015
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In this study, we show for the first time that the NMDA-R is
expressed by rat Schwann cells and that expression is increased after
PNS injury. The NMDA-R functions as an essential LRP1 co-
receptor in Schwann cells and thus, is required for cell signaling in
response to diverse LRP1 ligands, including α2M, tPA and matrix
metalloproteinase 9 (MMP9). Through its effects on cell signaling,
the NMDA-R supports Schwann cell migration and survival. The
NMDA-R also functions as an independent Schwann cell receptor
for tPA, activating ERK1/2 (also known as MAPK3 and MAPK1,
respectively) and promoting cell migration in response to tPA even
when LRP1 is unavailable. These studies identify important
activities for the NMDA-R in a non-neuronal cell type, the
Schwann cell, as an independent receptor for the protein ligand tPA
and as a co-receptor for LRP1.
RESULTS
NMDA-R subunits are expressed by cultured Schwann cells
To begin, we subjected extracts of primary cultures of rat Schwann
cells to immunoblot analysis using an NR1-subunit-specific
antibody. As a positive control, we examined extracts from rat
dorsal root ganglia (DRGs). We also examined PC12 cells.
Although some variants of PC12 cells are reported to express low
levels of NMDA-R (Edwards et al., 2007), in our PC12 cell line, the
NMDA-R is expressed and functional (Mantuano et al., 2013). As
shown in Fig. 1A, NR1-specific antibody detected a protein in
Schwann cell extracts with an apparent mass of 110–120 kDa. The
mass of this species corresponds to the known mass of the NR1
subunit. The abundance of NMDA-R NR1 subunit in Schwann cell
extracts was somewhat lower than in extracts of DRGs and PC12
cells. The mobility of the NR1 subunit band in Schwann cell
extracts was slightly increased compared with the controls, probably
reflecting differential glycosylation of this highly glycosylated gene
product (Everts et al., 1997; Lichnerova et al., 2015).
To confirm that the detected band was the NR1 subunit, we
transfected Schwann cells with NR1-specific small interfering RNA
(siRNA, denoted siNR1). Fig. 1B shows that the level of NR1
mRNA in Schwann cells was decreased by∼85% by gene silencing.
NR1 gene silencing also substantially decreased the intensity of the
110–120-kDa band in NR1 subunit immunoblots, confirming that
the detected band was the NR1 subunit (Fig. 1C). As a control, we
showed that NR1-specific siRNA had no effect on the cellular level
of β-actin. Fig. 1C also shows that the NR2B NMDA-R subunit was
detected in Schwann cell extracts by immunoblot analysis and
unchanged by NR1 siRNA.
Schwann cells that were transfected with NR1-specific siRNA or
with NTC siRNAwere studied by immunofluorescence microscopy
using primary antibody that detects NR1 subunit. Nuclei were
labeled with DAPI. Fig. 1D shows that cultured Schwann cells,
transfected with NTC siRNA, were uniformly immunopositive for
NR1. NR1 gene silencing eliminated the NR1 immunofluorescence
microscopy signal in essentially all of the cells.
NMDA-R is necessary for LRP1 signaling in Schwann cells
Binding of ligands to LRP1 regulates diverse cell signaling pathways
in Schwann cells (Mantuano et al., 2008a,b, 2010). In this study, we
examined ERK1/2 phosphorylation as an indicator of the
multifaceted LRP1 signaling response. Fig. 2A shows that the
LRP1 ligand activated α2M (α2M*) (10 nM) and the enzymatically
inactive tPA (EI-tPA) (12 nM), activated ERK1/2 in cultured
Schwann cells. To confirm that this signaling response requires
LRP1, we pre-treated Schwann cells with receptor-associated
protein (RAP, also known as LRPAP1), which was expressed as a
GST-fusion protein (GST–RAP) (150 nM). RAP is a well-
established LRP1 cell signaling antagonist (Strickland et al.,
2002). We also pre-treated cells with lactoferrin (150 nM), which
in neurons and neuron-like cells, functions similarly to RAP, binding
to LRP1 and preventing activation of cell signaling by other ligands
(Mantuano et al., 2013). RAP and lactoferrin both blocked ERK1/2
activation in Schwann cells in response to α2M* and EI-tPA.
In neurons, LRP1 signaling requires the NMDA-R as an essential
co-receptor (Bacskai et al., 2000; Qiu et al., 2002; Samson et al.,
2008; Martin et al., 2008; Sheng et al., 2008; Mantuano et al., 2013).
Other LRP1 co-receptors in neurons include Trk receptors and
p75NTR (Shi et al., 2009; Yoon et al., 2013; Stiles et al., 2013). Very
little is known about the molecular nature of the LRP1 signaling
system in other cell types. To test whether the NMDA-R is required
for LRP1 signaling in Schwann cells, first we pre-treated Schwann
cells with MK801 (1 µM), an uncompetitive antagonist of the
NMDA-R. Fig. 2B shows that MK801 blocked ERK1/2
phosphorylation in response to α2M* and EI-tPA. In control
Fig. 1. NMDA-R is expressed by cultured Schwann cells. (A) NR1 protein
was determined by immunoblot analysis in extracts of rat DRGs, Schwann cells
and PC12 cells. Equal amounts of cellular protein (60 μg) were loaded into
each lane. Blots were re-probed for β-actin as a loading control. (B) NR1mRNA
was determined by qRT-PCR in Schwann cells transfected with NTC or
NR1-specific siRNA (siNR1). (C) Primary cultures of Schwann cells were
transfected with NTC siRNA or siNR1. The levels of NR1 and NR2b were
determined by immunoblot analysis 48 h after transfection. Blots were re-
probed for β-actin as a loading control. (D) Immunofluorescence microscopy
was performed to detect NR1 immunoreactivity in Schwann cells transfected
with NTC or NR1-specific siRNA. Nuclei were stained with DAPI (blue).
Scale bars: 20 μm.
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experiments, we demonstrated that MK801 and the LRP1
antagonists, RAP and lactoferrin, do not independently regulate
phosphorylated (p-)ERK1/2 in Schwann cells (Fig. 2C).MK801 also
inhibited the ERK1/2 activation in response to a GST fusion protein
that contains the hemopexin domain of MMP9 (GST–PEX, 20 nM),
known to bind to LRP1 (Mantuano et al., 2008a,b) (Fig. 2D).
Next, we examined the effects of NR1 gene silencing on LRP1-
initiated cell signaling. In Schwann cells, that were transfected with
non-targeting control (NTC) siRNAand treatedwithα2M* or EI-tPA
for 10 min, ERK1/2 was activated. In cells transfected with NR1-
specific siRNA, the response to α2M* and EI-tPA was completely
blocked (Fig. 2E). Fig. 2F shows that, in Schwann cells transfected
with NTC siRNA, the response to EI-tPA (12 nM) was sustained
through 60 min. In cells transfected with NR1-specific siRNA,
ERK1/2 activation was blocked throughout the entire incubation
period. These NR1 gene silencing experiments support the results of
our MK801 studies and suggest that NMDA-R is essential for
activation of cell signaling by α2M* and tPA in Schwann cells.
The NMDA-R in Schwann cell migration and survival
Ligand binding to LRP1 in Schwann cells promotes cell migration
(Mantuano et al., 2008a,b). Although LRP1 controls multiple
signaling pathways that regulate cell migration, in response to LRP1
ligands, migration is stimulated mainly due to activation of ERK1/2
(Mantuano et al., 2008a,b, 2010). We tested the ability of MK801 to
block Schwann cell migration in response to EI-tPA and α2M*
using our previously described Transwell model system (Mantuano
et al., 2008a,b). Fig. 3 shows that, in absence of MK801, EI-tPA and
α2M* increased Schwann cell migration more than fivefold
(P<0.01). MK801 had no effect on Schwann cell migration in the
absence of LRP1 ligands; however, MK801 completely blocked the
response to EI-tPA and α2M*.
Next, we compared Schwann cells transfected with NR1-specific
or NTC siRNA. As shown in Fig. 4A,B, in cells transfected with
NTC siRNA, EI-tPA and α2M* promoted cell migration. The
response to EI-tPA and α2M* was entirely blocked by NR1 gene
silencing. These results and those of our MK801 studies
demonstrate that NMDA-R is essential in the pathway by which
tPA and α2M* promote Schwann cell migration.
LRP1 also has been implicated in Schwann cell survival (Campana
et al., 2006).We therefore tested the effects of NR1 gene silencing on
Schwann cell survival. Cells were exposed to low-serum medium
(LSM) or LSM supplemented with TNFα (50 ng/ml) for 18 h. Under
both sets of conditions, Schwann cell viability was compromised. The
extent of compromisewas significantly increased in cells in which the
NR1 gene was silenced (P<0.05) (Fig. 4C). We therefore conclude
that the effects of NMDA-R NR1 gene silencing are equivalent to
those observed when LRP1 is silenced or when its activity is
antagonized (Campana et al., 2006; Mantuano et al., 2008a,b).
Schwann cell NMDA-R activates cell signaling in response to
tPA independently of LRP1
In neurons, tPA can trigger cell signaling through a direct interaction
with the NMDA-R, independently of LRP1 (Nicole et al., 2001;
Macrez et al., 2010; Ng et al., 2012; Mantuano et al., 2013). To
determine whether the NMDA-R signals in response to tPA,
independently of LRP1 in Schwann cells, we treated Schwann
cells with 12 nM EI-tPA in the presence or absence of RAP
Fig. 2. Neutralizing the NMDA-R blocks ERK1/2 activation in
response to LRP1 ligands in Schwann cells. (A) Primary
cultures of Schwann cells were pre-treated with 150 nM GST–RAP
(RAP), 150 nM lactoferrin (LF) or with vehicle (PBS) for 30 min and
then with α2M* (10 nM) or EI-tPA (12 nM) for 10 min. (B) Schwann
cells were pre-treated with 1 µM MK801 (+) or with vehicle (−) for
30 min and thenwith α2M* (10 nM), EI-tPA (12 nM) or vehicle (PBS)
for 10 min. (C) Schwann cells were treated with GST–RAP
(150 nM), lactoferrin (150 nM) or MK801 (1 µM) for 30 min.
(D) Schwann cells were pre-treated with 1 µM MK801 (+) or with
vehicle (−) for 30 min and then with GST (20 nM), EI-tPA (12 nM),
or GST–PEX (20 nM) for 10 min. (E) Schwann cells in which NR1
was silenced and control cells transfected with NTC siRNA were
treated with EI-tPA (12 nm) or α2M* (10 nM) for 10 min. (F) Primary
cultures of Schwann cells in which NR1 was silenced and control
cells transfected with NTC siRNA were treated with EI-tPA (12 nm)
for various times up to 1 h. Equal amounts of cellular protein (40 μg)
were loaded into each lane and subjected to SDS-PAGE.
Immunoblot analysis was performed to detect phosphorylated
ERK1/2 (p-ERK) and total ERK1/2 (T-ERK). Each blot represents
3–5 independent studies.
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for up to 60 min. At 15 min, RAP blocked the response to EI-tPA,
confirming the results of experiments reported in Fig. 1A. However,
by 30 min, ERK1/2 was activated even when binding of EI-tPA to
LRP1 was prevented with RAP (Fig. 5A). The activity of RAP,
blocking ERK1/2 phosphorylation in response to EI-tPA, was also
overcome by increasing the EI-tPA concentration (Fig. 5B). These
results suggest that in Schwann cells, as in PC12 and N2A cells
(Mantuano et al., 2013), EI-tPA signals by binding to the NMDA-R,
independently of LRP1; however, LRP1 facilitates a more rapid
response or increases the sensitivity of the system.
As a control, we studied the Schwann cell response to 10 nM α2M*
as a function of time, up to 60 min, in the presence or absence of RAP.
We selected α2M* for these control experiments because the binding
affinity of α2M* for LRP1 is much higher than the affinity of tPA for
LRP1 (Neyet al., 1985;Hussaini et al., 1990;Buet al., 1992).Although
ERK1/2was robustlyactivatedbyα2M* in the absence ofRAP through
the entire 60 min timecourse, when RAP was present, p-ERK1/2
was not observed (Fig. 5C). Increasing the concentration of α2M* to
60 nM also failed to overcome the activity of RAP (Fig. 5D). Thus, for
α2M*-initiated cell signaling in Schwann cells, unlike cell signaling
stimulated by EI-tPA, the requirement for LRP1 appears absolute. For
both EI-tPA and α2M*, the requirement for NMDA-R is absolute.
To further test whether EI-tPA interacts with the NMDA-R to
regulate Schwann cell physiology in the absence of LRP1, we
examined the ability of EI-tPA to stimulate Schwann cell migration
in the presence of RAP. As shown in Fig. 6A, Schwann cell
migration in response to 12 nM EI-tPA was blocked by 150 nM
RAP. By contrast, 60 nM EI-tPA overcame the inhibitory effects of
RAP, stimulating cell migration by 5.4±0.3 fold (mean±s.e.m.). As
a control, we examined cell migration in response to different
concentrations of α2M*. As shown in Fig. 6B, α2M* failed to
promote Schwann cell migration in the presence of 150 nM RAP
when added at a concentration of 10 nM or 60 nM.
As a second approach to study the effects of EI-tPA on Schwann
cell migration in the absence of LRP1, we silenced LRP1 expression
in Schwann cells as previously described (Mantuano et al.,
Fig. 3. NMDA-R antagonism inhibits the ability of LRP1 ligands to
promote Schwann cell migration. (A) Images of Schwann cells that migrated
across Transwell membranes to the lower surfaces. The cells were pre-treated
with MK801 (1 µM) for 15 min and then treated with EI-tPA (12 nM), α2M*
(10 nM) or vehicle (PBS). The LRP1 ligands were added to the Transwell
chambers. Migration was allowed to proceed for 4 h. (B) Quantification of cell
migration results. Data are expressed as the mean±s.e.m. (n=6–8, *P<0.01
compared with the vehicle control).
Fig. 4. NR1 gene silencing in Schwann cells blocks cell migration in
response to LRP1 ligands. (A) Images of Schwann cells, transfected with
NTC or NR1-specific siRNA, which migrated to the underside surface of
Transwell membranes. The cells were treated with EI-tPA (12 nm), α2M*
(10 nM) or vehicle (PBS). Migration was allowed to proceed for 4 h.
(B) Quantification of cell migration results. Data are expressed as the
mean±s.e.m. (n=6, *P<0.01 compared with the vehicle control). (C) Schwann
cell death was measured using the cell death ELISA in cells transfected with
NTC siRNA or NR1-specific siRNA, after culturing for 4 h in complete medium
(10% FBS, CM), Sato medium, 0.5% FBS-containing medium (LSM), or LSM
plus TNFα (50 ng/ml). The mean±s.e.m. is shown (n=4, *P<0.05).
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2008a,b). Compared with cells transfected with NTC siRNA,
LRP1-silenced cells demonstrated >95% reduction in LRP1 mRNA
(results not shown). Fig. 6C shows that LRP1 gene silencing
blocked Schwann cell migration in response to 12 nM EI-tPA. In
response to 60 nM EI-tPA, a breakthrough response was observed;
migration was stimulated 3.2±0.2 fold (P<0.01). Schwann cell
migration in response to 12 nM EI-tPA or 60 nM EI-tPAwas totally
inhibited by MK801 (Fig. 6D).
Enzymatically active and inactive tPA activate cell signaling
in Schwann cells similarly
When the enzymatic activity of tPA is not blocked, the NR1 subunit
of the NMDA-R may be cleaved (Nicole et al., 2001). Active tPA
also may release LRP1 from the surfaces of cells (Polavarapu et al.,
2007). We therefore conducted cell signaling experiments to
determine whether enzymatically active tPA (EA-tPA) and
inactive tPA yield equivalent results. Fig. 7A shows that EA-tPA
activated ERK1/2 in cultured Schwann cells. The response was
blocked by RAP when the concentration of EA-tPA was 12 nM;
however, the inhibitory activity of RAP was overcome by higher
concentrations of EA-tPA (60 nM). Extending the incubation time
also overcame the inhibitory activity of RAP (Fig. 7B). ERK1/2
activation in response to EA-tPAwas blocked by MK801 (Fig. 7C).
These results suggest that EA-tPA and EI-tPA activate cell signaling
in Schwann cells equivalently.
Sciatic nerve crush injury promotes expression of Schwann
cell NMDA-R
In rats, LRP1 expression is robustly increased in Schwann cells in
response to PNS injury (Campana et al., 2006). Schwann cells
account for >90% of the mRNA present in the un-injured PNS and
in the injured PNS for up to 2–3 days, before inflammatory cells
infiltrate the injury site in significant numbers (Asbury and Johnson,
1978). We therefore performed quantitative real-time PCR
(qRT-PCR) to test the effects of sciatic nerve crush injury on the
NMDA-R subunit expression in vivo. Fig. 8A shows that LRP1
mRNA was significantly increased in the distal segment of the
sciatic nerve, 24 h after crush injury. This result confirms our
previous study, in which we proved that the increase in LRP1
mRNA was due to regulation of Schwann cell LRP1 gene
expression (Campana et al., 2006). Sciatic nerve crush injury also
increased expression of NMDA-R subunits in distal segments,
including NR1 (P<0.05, Fig. 8B) and NR2b (P<0.05, Fig. 8D).
Although a trend towards increased NR2a mRNA expression was
observed, the trend was not statistically significant (Fig. 8C).
MK801 blocks Schwann cell LRP1 signaling in vivo
Direct injection of the hemopexin domain of MMP-9 (MMP9-PEX)
into crush-injured sciatic nerves activates ERK1/2 in Schwann cells
in a response that is LRP1 dependent, as determined by co-injection
of RAP (Mantuano et al., 2008a,b). ERK1/2 activation is not
observed when MMP9-PEX is injected into uninjured nerves,
probably because the level of Schwann cell LRP1 is extremely low
in the uninjured PNS. In this study, for the first time, we injected EI-
tPA into sciatic nerves, immediately distal to the injury site, 24 h
after crush injury. We also injected MMP9-PEX, to collect results
with a second LRP1 ligand. Fig. 8E shows that in control, uninjured
nerves, p-ERK1/2 was minimally activated, as anticipated
(Mantuano et al., 2008a,b). When rats were treated systemically
with MK801 for 45 min prior to harvesting uninjured nerves, little
or no effect on ERK1/2 activation was observed.
p-ERK1/2 remained only modestly activated in crush-injured
sciatic nerves when the nerves were injected with vehicle, and once
again, systemic pre-treatment with MK801 failed to significantly
affect this result. By contrast, as shown in Fig. 8E, direct injection of
EI-tPA into crush-injured sciatic nerves robustly activated ERK1/2.
Systemic treatment of the rats withMK801 (intraperitoneal injection),
for 30 min prior to injecting EI-tPA, blocked the response to EI-tPA.
MMP9-PEX also activated ERK1/2 in crush-injured sciatic nerves, as
anticipated (Mantuano et al., 2008a,b), and the response to MMP9-
PEX was blocked by systemic administration of MK801. Overall,
MK801 inhibited cell signaling in vivo in response to one ligand
(MMP9-PEX), which is known to bind only to LRP1, and to a second
ligand (EI-tPA), which binds to LRP1 and/or the NMDA-R. These
results suggest that the NMDA-R is essential for LRP1 signaling in
Schwann cells in vivo in the injured PNS.
Fig. 5. tPA initiates NMDA-R-dependent cell signaling in the absence of
LRP1 with delayed kinetics. (A) Primary cultures of Schwann cells were pre-
treated with 150 nM GST–RAP (+) or with vehicle (−) for 30 min and then
EI-tPA (12 nm) for the indicated times. (B) Schwann cells were pretreated with
GST–RAP (150 nm) or with vehicle for 30 min and then with increasing
concentrations of EI-tPA (12–60 nM) for 10 min. (C) Schwann cells were
pre-treated with 150 nM GST–RAP (+) or with vehicle (−) and then α2M*
(10 nM) for up to 60 min. (D) Schwann cells were treated with increasing
concentrations of α2M* for 10 min. Equal amounts of cellular protein (40 μg)
were loaded into each lane and immunoblot analysis was performed to detect
phosphorylated ERK1/2 (p-ERK) and total ERK1/2 (T-ERK).
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To confirm that ERK1/2 activation occurred in Schwann cells
when EI-tPA was injected into crush-injured sciatic nerves, we
harvested tissue distal to the crush injury site and performed
immunofluorescencemicroscopymicroscopy to detect p-ERK1/2, as
previously described (Mantuano et al., 2008a,b). Fig. 8F shows that
p-ERK1/2 immunofluorescence microscopy was clearly present in
nucleated crescent-shapedSchwann cells followingEI-tPA injection.
In animals that were pre-treatedwithMK801 systemically, Schwann-
cell-associated p-ERK1/2 immunofluorescence microscopy
appeared decreased. Although immunofluorescence microscopy is
not an appropriate technique tomeasure antigen levels quantitatively,
the studies shown in Fig. 8F confirm that ERK1/2 is activated in
Schwann cells in vivo when EI-tPA is injected into injured sciatic
nerves and the NMDA-R is un-inhibited.
DISCUSSION
In this study, for the first time, we demonstrated that rat Schwann
cells express NMDA-R. We also elucidated an essential role for
Schwann cell NMDA-R as a signaling receptor in response to
proteins known to be present in the injured PNS. Our results support
a model in which the NMDA-R can be an important regulator of
Schwann cell physiology. Schwann cells are known to release
glutamate that interacts with neuronal NMDA-R (Wu et al., 2005);
however, only a few previous reports have shown that NMDA-Rs
are expressed by glia and might have significant functions in these
cells. Satellite glial cells in DRGs apparently express the NMDA-R,
which might contribute to interactions with neurons (Castillo et al.,
2013). NMDA-R activation in satellite cells has been linked
to sensitization of nociceptors and peripheral hyperalgesia
(Ferrari et al., 2014). The NMDA-R also has been identified
in oligodendrocyte precursor cells, where it might function in
differentiation and myelination (Li et al., 2013). In astrocytes, the
NMDA-R regulates the production of the neuronal NMDA-R co-
agonist D-serine (Van Horn et al., 2013). Our new results suggest a
highly expanded scope of activity for the NMDA-R as a receptor for
protein ligands in Schwann cells in the injured PNS.
LRP1 has been identified as a regulator of inflammation and tissue
remodeling in diverse cell types (Gonias and Campana, 2014). The
increase in Schwann cell LRP1 expression that accompanies PNS
injury is consistent with this model. When the LRP1 gene is deleted
in Schwann cells in mice, numerous abnormalities are observed
following sciatic nerve injury, including accelerated demyelination,
increased infiltration of the nerve by inflammatory cells, and
abnormal regeneration (Orita et al., 2013). Because injecting RAP
directly into injured sciatic nerves blocks LRP1 signaling and
promotes Schwann cell death (Campana et al., 2006;Mantuano et al.,
2008a,b), we hypothesize that in nerve injury, endogenously
produced LRP1 ligands with agonistic signaling activity, such as
MMP9 or tPA, activate the LRP1 signaling system, preventing the
changes observed in conditional LRP1 gene knockout mice.
Results presented in this study demonstrated that the NMDA-R is
required for activation of ERK1/2 in response to multiple LRP1
ligands (α2M*, tPA andMMP9-PEX) in Schwann cells in vitro. The
requisite role of the NMDA-R in Schwann cell LRP1 signaling
suggested that previously demonstrated activities of Schwann cell
LRP1 also might require the NMDA-R.We tested this hypothesis in
a variety of experiments. The NMDA-R was required for LRP1-
ligand-stimulated cell migration. Furthermore, NMDA-R NR1 gene
silencing compromised Schwann cell viability under stressful cell
culture conditions. The effects of NR1 gene silencing in cell death
ELISA assays were similar to those observed when we silenced
LRP1 gene expression in Schwann cells (Campana et al., 2006).
Fig. 6. tPA promotes Schwann cell migration by binding
to the NMDA-R, independently of LRP1. (A) Primary
cultures of Schwann cells were pre-treated with 150 nM
GST–RAP (+) or with vehicle (−) for 15 min and then with the
indicated concentration of EI-tPA (12 or 60 nM). The EI-tPA
and RAP were added to the Transwell chambers. Migration
was allowed to proceed for 4 h. (B) Schwann cells were pre-
treated with 150 nM GST–RAP (+) or with vehicle (−) and
then with α2M* at the indicated concentration (10 or 60 nM)
before migration was allowed to proceed for 4 h. (C) Schwann
cells, transfected with NTC or NR1-specific siRNA, were
treated with the indicated concentration of EI-tPA (12 or
60 nM) or vehicle (PBS) and allowed to migrate for 4 h.
(D) Schwann cells were pre-treated with MK801 (1 µM) for
15 min and then treated with EI-tPA at the indicated
concentration (12 or 60 nM). Data are expressed as the
mean±s.e.m. (n=6–8, *P<0.01 compared with the
vehicle control).
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Finally, treating rats systemically withMK801 blocked the ability of
MMP9-PEX and EI-tPA to activate ERK1/2 in Schwann cells when
the protein ligands were injected directly into crush-injured sciatic
nerves. These results suggest that NMDA-R functions in Schwann
cell signaling and as an essential Schwann cell LRP1 cell signaling
co-receptor in vivo. By analogy with the role of Schwann cell LRP1
in vivo (Orita et al., 2013), we hypothesize that Schwann cell
NMDA-R might be important in determining the rate and extent of
demyelination following PNS injury, in preventing excessive neuro-
inflammation, and in functional nerve regeneration. Further work
using conditional gene deletion model systems will be necessary to
further explore the activity of Schwann cell NMDA-R in vivo,
independently of neuronal NMDA-R.
We applied two methods to show that Schwann cell signaling
responses require the NMDA-R: pharmacological antagonism and
gene silencing. To show that LRP1 is required, we blocked responses
with two separate LRP1 antagonists, RAPand lactoferrin. In previous
studies, we also applied LRP1 gene silencing with equivalent results
(Mantuano et al., 2008a,b, 2010). To test the role of the NMDA-R in
Schwann cell LRP1 signaling, we chose to examine a variety of LRP1
ligands. This was important because the LRP1 ligands studied here
bind to alternative cellular receptors that might also trigger cell
signaling. For example, in prostate cancer cells, activated α2M might
bind to GRP78, which becomes externalized and associated with the
cell surface (Misra et al., 2011). Similarly, tPA might bind to cell
surface annexin A2, eliciting diverse responses in endothelial cells
and other cell types (Luo and Hajjar, 2013). The ability of α2M*, EI-
tPA and MMP9 to activate ERK1/2 similarly and the ability of two
separate LRP1 signaling antagonists (RAP and lactoferrin) to block
these responses confirms the essential role of LRP1.
Fig. 8. NMDA-R subunits are expressed at increased levels in the injured
sciatic nerve and are essential for Schwann cell LRP1 signaling in vivo.
(A) Rat sciatic nerves were subjected to crush injury. Nerve tissue distal to the
crush injury site and proximal to the injury site was recovered at the time of
killing, 24 h after surgery. Contralateral nerve tissue was recovered as a
control. LRP1 (A), NR1 (B), NR2a (C) and NR2b (D) mRNA levels were
determined in each nerve tissue sample by qRT-PCR. mRNA expression
results are presented as the fold increase in mRNA, relative to the contralateral
nerve (mean±s.e.m., n=4, *P<0.05). (E) Rats were subjected to sciatic nerve
crush injury (injured) or sham operation (uninjured). After 24 h, the rats were
treated systemically with 0.1 mg/kgMK801 (+) or with vehicle (−). After another
30 min, EI-tPA, MMP9-PEX (2 μl of 5 µM stock) or vehicle was injected directly
into crush-injured nerves. Uninjured nerves were not injected. Nerve tissue
distal to the injury site was harvested 15 min later. Immunoblot analysis was
performed to detect phosphorylated ERK1/2 (p-ERK) and total ERK1/2
(T-ERK). The figure shows results from two separate animals for each
condition with crush-injured nerves. A single replicate is shown for the sham
operation (+ or−MK801). (F) Rats were subjected to sciatic nerve crush injury,
treated with MK801 or with vehicle, and injected with EI-tPA (directly into the
injured sciatic nerve). Immunofluorescence microscopy was performed to
detect p-ERK1/2 distal to the injury site. Images were acquired at 200×
magnification. Scale bar: 10 μm. Note the presence of p-ERK1/2
immunoreactivity (green) in Schwann cell crescents (see arrows). DAPI (blue)
identifies nuclei. The images are representative of those acquired in six
separate animals.
Fig. 7. Enzymatically active tPA activates ERK1/2 in Schwann cells in a
similar manner to EI-tPA. (A) Primary cultures of Schwann cells were pre-
treated with 150 nM GST–RAP (+) or with vehicle (−) for 30 min and then with
increasingconcentrations of enzymatically active tPA (EA-tPA, 12-60 nM)orwith
12 nM EI-tPA as a control. (B) Schwann cells were pretreated with GST–RAP
(150 nM) or with vehicle for 30 min and then EA-tPA (12 nM) for 15 or 30 min.
Cells were treated with 12 nM EI-tPA for 15 min as a control. (C) Schwann cells
were pre-treatedwith 1 µMMK801 (+) or with vehicle (−) for 30 min and thenwith
EA-tPA (12 nM) for 10 min. Equal amounts of cellular protein (40 μg) were
loaded into each lane and immunoblot analysis was performed to detect
phosphorylated ERK1/2 (p-ERK) and total ERK1/2 (T-ERK).
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tPA might be unique compared with the other LRP1 ligands
studied here because tPA activated ERK1/2 in Schwann cells when
LRP1 was blocked, albeit with delayed kinetics. The activity of the
NMDA-R as an independent but less-efficient tPA signaling
receptor in the absence of LRP1 in Schwann cells is equivalent to
the activity observed previously in PC12 and N2a cells (Mantuano
et al., 2013). These data support a model in which tPA binds with
low affinity to LRP1 or the NMDA-R. Simultaneous coupling to
both cell surface receptors apparently provides an optimal response,
increasing the sensitivity of the signaling system. In addition to
binding to the NMDA-R, tPA might cleave NMDA-R subunits in
reactions that affect receptor function (Nicole et al., 2001;
Fernández-Monreal et al., 2004;). In our studies, we examined
enzymatically inactive tPA (EI-tPA) and confirmed that active tPA
(EA-tPA) generates similar signaling responses. The signaling
activity demonstrated by EI-tPA and the effects of EI-tPA on
Schwann cell migration show that tPA is an active signaling protein
in Schwann cells, independently of its proteolytic activity.
Although our results are the first to suggest that tPA might
regulate Schwann cell physiology by binding directly to Schwann
cell NMDA-R, previous studies have shown that tPA is indeed a
robust regulator of the response to PNS injury. tPA is expressed by
Schwann cells in culture (Alvarez-Buylla and Valinsky, 1985) and
in vivo (Akassoglou et al., 2000), and is up-regulated in the sciatic
nerve, together with other fibrinolysis proteins, following nerve
injury (Siconolfi and Seeds, 2001). Akassoglou et al. (2000),
demonstrated that tPA deficiency in mice exacerbates demyelination
and axonal damage following sciatic nerve injury. Although these
effects have been attributed to excessive fibrinogen deposition in the
injured nerve, our data suggest that interaction of tPAwith Schwann
cell NMDA-R and LRP1 might have also contributed to these
results.
Our new model in which the NMDA-R functions as a cell
signaling receptor in Schwann cells alone, and as part of a cell
signaling system with LRP1, does not preclude the function of other
gene products as part of the NMDA-R–LRP1 signaling system. In
neurons, post-synaptic density protein-95 (PSD-95, also known as
DLG4) is an important component of this signaling system,
physically coupling LRP1 to the NMDA-R (May et al., 2004).
This interaction might be potentiated by ligand binding to LRP1
(Mantuano et al., 2013). Trk receptors also are required for cell
signaling downstream of LRP1 and the NMDA-R in neurons and
neuron-like cells (Shi et al., 2009; Yoon et al., 2013). Becausewe do
not have evidence for the function of Trk receptors in LRP1
signaling in Schwann cells (Shi et al., 2009), the activity of other
receptor tyrosine kinases merits consideration.
In conclusion, we have shown that Schwann cells express the
NMDA-R and that this receptor is a potentially important regulator
of Schwann cell physiology in PNS injury. Schwann cell NMDA-R
functions as a co-receptor for diverse LRP1 ligands and as an
independent receptor for tPA, activating cell signaling and
promoting Schwann cell migration. The NMDA-R also promotes
Schwann cell survival under challenging conditions.
MATERIALS AND METHODS
Proteins and reagents
α2M was purified from human plasma by the method of Imber and Pizzo
(1981) and activated for binding to LRP1 by dialysis against 200 mM
methylamine HCl (α2M*), as previously described (Gonias et al., 1982).
Modification of α2M by methylamine was confirmed by demonstrating the
characteristic increase in α2M electrophoretic mobility by non-denaturing
PAGE (Barrett et al., 1979). EI-tPA and EA-tPA were purchased from
Molecular Innovations (Southfield, MI). The NMDA-R antagonist,
MK801, was from Calbiochem. Lactoferrin and fibronectin were
purchased from Sigma-Aldrich (St Louis, MO). The LRP1-ligand-binding
antagonist RAP was expressed as a GST fusion protein (GST–RAP) in
bacteria and purified as previously described (Herz et al., 1991). The
hemopexin domain of MMP9, which includes the LRP1-binding site in
MMP9 (MMP9-PEX; Mantuano et al., 2008a,b), was expressed as a GST
fusion protein in bacteria. MMP9-PEX was partially purified by selective
detergent extraction (Webb et al., 1998) and then purified to homogeneity
by chromatography on a glutathione–Sepharose column (Mantuano et al.,
2008a,b). All GST fusion proteins were subjected to urea treatment, dialysis
and chromatography on Detoxi-Gel endotoxin-removing columns (Pierce).
For immunoblotting experiments, rabbit polyclonal antibodies that detect p-
ERK1/2, total ERK1/2, the NR1 subunit of the NMDA-R and the NR2b
subunit of NMDA-R, and horseradish-peroxidase-conjugated secondary
antibody were purchased from Cell Signaling Technologies (Beverly, MA).
For immunofluorescence microscopy studies, polyclonal antibody against
the NR1 subunit was from Abcam (Cambridge, MA) and rabbit monoclonal
antibody that detects p-ERK1/2 was from Cell Signaling Technologies
(Beverly, MA).
Cell culture
Sciatic nerves were isolated from 1-day-old Sprague Dawley rats. Schwann
cells were isolated and enriched by removing fibroblasts using fibronectin-
specific antibody and rabbit complement cytolysis, as described previously
(Campana et al., 2006). The final preparations consisted of 98% Schwann
cells, as determined by immunofluorescence microscopy for S100β, which
is a specific Schwann cell marker. Primary cultures of Schwann cells were
maintained in low-glucose Dulbecco’s modified Eagle’s medium (DMEM;
Hyclone) containing 10% FBS (Hyclone), 100 U/ml penicillin, 100 μg/ml
streptomycin, 21 μg/ml bovine pituitary extract and 4 μm forskolin
(complete medium) at 37°C under humidified 5% CO2. Schwann cell
cultures were passaged no more than six times before conducting
experiments. Rat PC12 pheochromocytoma cells were obtained from the
ATCC (catalog no. CRL-1721) and cultured in high-glucose DMEM
(Invitrogen) containing 10% FBS, 5% heat-inactivated horse serum (Omega
Scientific Inc.), penicillin (100 units/ml) and streptomycin (1 mg/ml).
Gene silencing
Rat NR1-specific siRNAON-TARGETplus SMARTpool, which targets the
NR1 subunit of the NMDA-R, and pooled non-targeting control (NTC)
siRNAwere from Dharmacon. Schwann cells (2×106) were transfected with
NR1-specific siRNA (50 nM) or with NTC siRNA (50 nM) by
electroporation using the Cell Line Nucleofector Kit V (Amaxa). The
degree of gene silencing was determined at the mRNA level by qRT-PCR
and at the protein level by immunoblot analysis. Cell signaling andmigration
experiments were performed 24–36 h after introducing the siRNAs.
qRT-PCR
Total RNA was isolated using the RNeasy Kit (Qiagen, Valencia, CA,
USA). cDNA was synthesized with the iScript cDNA Synthesis Kit (Bio-
Rad, Hercules, CA, USA). qRT-PCR was performed using a System 7300
instrument (Applied Biosystems, Carlsbad, CA) and a one-step program:
95°C, 10 min; 95°C, 30 s, 60°C, 1 min for 40 cycles (primer sequences are
available from the corresponding author upon request). GAPDH mRNA
levels were determined in each sample as a normalizing gene. We and others
(Macdonald et al., 2001; Campana et al., 2006) have shown that GAPDH is
an appropriate and relatively stable housekeeping gene in peripheral nerve
injury. mRNA levels were calculated by the relative quantity (ΔΔCt)
method. Experiments were performed in triplicate, with internal duplicate
determinations.
Immunofluorescence microscopy
Schwann cells in culture were fixed with fresh 4% paraformaldehyde in
20 mM sodium phosphate, 150 mMNaCl, pH 7.4 (PBS) for 15 min at 22°C
and then permeabilized in 0.25% Triton X-100 in PBS (PBS-T).
Nonspecific binding sites were blocked with 1% BSA in PBS-T for 30 min
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at room temperature. Cells then were incubated overnight at 4°Cwith primary
antibody against NR1 subunit in PBS with 0.5% Tween 20 and 1% BSA.
Next, cells were incubated with Alexa-Fluor-488-conjugated secondary
antibodies in 1%BSA for 1 h at 22°C in the dark. Preparations were mounted
on slides using Pro-long Gold with DAPI for nuclear labeling. Images were
captured using a Leica DMIRE2 fluorescence microscope.
Immunoblot analysis
Schwann cells were plated at a density of 2×106 cells per well in serum-
containing medium and cultured until ∼70% confluent. The cultures were
then transferred into serum-free medium (SFM) for 1 h before adding α2M*,
EI-tPA, MMP9-PEX or vehicle. MK801 (1 µM), GST–RAP (150 nM),
lactoferrin (150 nM) or GST were added 30 min before adding stimulants,
as indicated. Incubations were conducted for 10 min. The cells were then
rinsed twice with ice-cold PBS. Cell extracts were prepared in RIPA buffer
(PBS with 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS,
protease inhibitor mixture and sodium orthovanadate). The protein
concentration in cell extracts was determined by bicinchoninic acid assay.
An equivalent amount of cellular protein (40 µg) was subjected to 10%
SDS-PAGE and electrotransferred onto nitrocellulose membranes. The
membranes were blocked with 5% nonfat dried milk powder in 20 mMTris-
HCl, 150 mM NaCl, pH 7.4 with Tween 20 and incubated with primary
antibodies. The membranes were then washed and treated with horseradish-
peroxidase-conjugated secondary antibodies for 1 h. Immunoblots were
developed by enhanced chemiluminescence (Perkin Elmer). Each
experiment was performed at least three times.
Cell migration assays
Schwann cell migration was studied using 6.5-mm Transwell chambers with
8 µm pores (Corning Costar, Corning, NY), as previously described
(Mantuano et al., 2008a,b). The bottom surface of each membrane was
coated with 10 µg/ml fibronectin. We selected fibronectin as the substratum
because, after peripheral nerve injury, fibronectin expression is induced to
provide a provisional matrix for nerve regeneration (Akassoglou et al.,
2000). Schwann cells in Sato medium (Bottenstein and Sato, 1980)
supplemented with 1 mg/ml BSAwere treated with α2M* (10 nM), EI-tPA
(12 nM) or vehicle for 10 min at 37°C. In some cases, the cells were pre-
treated with MK801 (1 µM) or GST–RAP (150 nM) prior to adding LRP1
ligands. Reagents were added at the same concentration to the medium in the
Transwell chambers. The bottom chamber contained 10% FBS. Cells (105)
were transferred to the top chamber of each Transwell chamber and allowed
to migrate at 37°C in 5% CO2. After 4 h, the upper surface of each
membrane was cleaned with a cotton swab. The membranes then were
stained with Diff-Quik (Dade-Behring, Deerfield, IL). The number of cells
on the bottom surface of each membrane was counted. Four fields were
examined on each filter. Each condition was studied in triplicate.
Cell death studies
Primary cultures of Schwann cells transfected with NTC siRNA or NR1-
specific siRNAwere plated at 104 cells per well in 96-well plates coated with
10 μg/ml fibronectin. Cells were cultured overnight in complete medium.
The cells were then retained in complete medium, re-equilibrated in DMEM
containing 0.5% FBS (low-serum medium, LSM), transferred to Sato media
(Bottenstein and Sato, 1980), or treated with TNFα (50 ng/ml) in LSM for
18 h. Cell death was measured using the cell death ELISA (Roche), a
colorimetric assay that measures intracytoplasmic oligonucleosomes
(Mantuano et al., 2008a,b).
Cell signaling in sciatic nerves in vivo
Experiments were performed using adult male Sprague-Dawley rats (200 g)
from Harlan Laboratories (San Diego, CA), which were housed in pairs with
a 12-h-light–12-h-dark cycle and ad libitum access to food and water. For
surgery, rats were anesthetized with 2% isoflurane (IsoSol; VedCo,
St. Joseph, MO). Using a sterile field, the left sciatic nerve was crushed
once for 2 s at the sciatic nerve notch with flat forceps (Myers et al., 2003).
The muscle layer then was closed using 6.0 silk sutures, followed by the
skin. After 12 h, when Schwann cell LRP1 expression is substantially
increased (Campana et al., 2006), rats were re-anesthetized and treated by
intraperitoneal injection with either MK801 (0.1 mg/kg) or vehicle (PBS).
30 min later, 2.0 µl of EI-tPA, MMP9-PEX (5 µM stock) or vehicle (PBS)
(n=4/group) was injected directly into the sciatic nerve fascicle at the crush
injury site. Nerve tissue distal to the crush injury site (0.3 cm) was collected
15 min after injecting the LRP1 ligands, together with contralateral nerve. In
control experiments, un-injured rat sciatic nerves were injected with EI-tPA,
MMP-PEX (5 µM stock) or PBS (n=4/group). Nerve tissue was harvested
15 min later. Extracts of sciatic nerve were isolated in RIPA buffer for
immunoblot analysis. For immunofluorescence microscopy microscopy
studies (see below), the rats were perfused transcardially with 4%
paraformaldehyde in 0.1 M phosphate buffer, pH 7.4 prior to collecting
sciatic nerve tissue. The rats were killed by intraperitoneal injection of an
overdose of anesthetic cocktail containing ketamine (100 mg/kg body
weight; Phoenix Scientific, St Joseph, MO) and xylazine (10 mg/kg body
weight; Boerhinger Pharmaceutical, St. Joseph, MO) followed by cervical
dislocation. All procedures were performed according to protocols approved
by the University of California, San Diego Committee on Animal Research,
and conform to the NIH Guidelines for Animal Use.
Immunofluorescence microscopy analysis of crush-injured
sciatic nerve
Distal sciatic nerve (0.3 cm) was recovered. The resected tissue was
immersed in fixative for 2 h at 4°C and then transferred to 20% sucrose in
PBS overnight. Serial 10 µm sections were prepared using a cryostat and
mounted on Superfrost Plus Micro Slides (VWR, West Chester, PA).
Polyclonal primary antibody, specific for phosphorylated ERK1/2 (1:500),
was applied overnight at 4°C. After washing with Tris-buffered saline with
Tween 20 three times, the sections were incubated with Alexa-Fluor-488-
conjugated goat anti-rabbit-IgG antibody (5 µg/ml) for 1 h. In control
studies, the primary antibody was omitted; no specific immunoreactivity
was observed. Nuclei were stained with mounting medium containing DAPI
(Invitrogen, Carlsbad, CA). All slides were covered with slips and
visualized using a Leica DMIRE2 fluorescence microscope. Images were
obtained using a 63× oil-immersion objective and a Hamamatsu digital
camera with SimplePCI software.
Statistical analysis
For all of the presented studies, replicates refer to separate experiments,
typically performed with internal duplicates or triplicates. Results of cell
migration, cell death, and in vivo cell signaling experiments were subjected
to analysis of variance (ANOVA). A Tukey’s post hoc analysis was
performed to assess differences between treatment groups.
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